NRC

AI MemoPost-earnings T+1

NRC Health

As of 2026-07-29/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings showed strong recurring-contract growth • 2026-07-29

Expected move: +26%

Biggest risk

Revenue growth was only 4%, GAAP results remained loss-making, and free cash flow was near breakeven. The packet contains no verified post-print analyst revisions, estimate changes, or detailed guidance update.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The Q2 print supports a constructive view: TRCV grew 11% year over year, management cited strong go-to-market execution and product commercialization, and Governance Institute bookings were the strongest in seven years. [#SEC-8K-2026-07-28]

Research note

Recommendation

—

Confidence

medium

As of

2026-07-29

Base target

$23

p=55%

Bull target

$27

p=20%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print scrutiny of cash conversion
Commercialization and recurring-value expansion
The Q2 print supports a constructive view: TRCV grew 11% year over year, management cited strong go-to-market execution and product commercialization, and Governance Institute bookings were the strongest in seven years.

BearKey bullets

Adjustment-related cash payments and GAAP losses could weigh on investor confidence.
Forward-looking statements remain subject to significant risks and uncertainties.
[#SEC-8K-2026-07-28]

WatchKey bullets

Q2 2026 earnings showed strong recurring-contract growth

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $23 (p=55%)

Bull/Bear spread: +48% / -2%

Vs latest close: Bull +48% · Base +26% · Bear -2%

Scenario probabilities

Bull Target: $27 (p=20%)Base Target: $23 (p=55%)Bear Target: $18 (p=25%)

Commentary

Primary-source earnings tone is constructive on TRCV growth, execution, commercialization, and bookings, but the financial quality is mixed because free cash flow was nearly zero. The packet does not establish the post-release price reaction or provide verified analyst target and estimate revisions; missing reaction data is not positive evidence. Social and options coverage are unavailable, so confidence remains moderate.

As of 2026-07-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print scrutiny of cash conversion
Commercialization and recurring-value expansion

Scenarios

Bull Target (Scenario probability)

$27 / p=20% prob

Base Target (Scenario probability)

$23 / p=55% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Price $18 as of 2026-07-29

Nearest Scenario: Bear (∆ 2%)

Targets vs latest close: Bull +48% · Base +26% · Bear -2%

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-07-29
Q2 2026 earnings showed strong recurring-contract growth
NRC reported Q2 TRCV of $151.9 million, up 11% year over year, with revenue up 4% to $35.4 million and adjusted EBITDA of $9.4 million. Management also cited strong execution, product commercialization, and seven-year-high Governance Institute bookings, while positioning the company for a strong second half. [#SEC-8K-2026-07-28]
Prob 75.00% • Move 4.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-print scrutiny of cash conversion
2026-08-31
Despite positive adjusted earnings, GAAP net loss was $3.3 million, operating cash flow was $1.4 million, and free cash flow was only $0.1 million after approximately $2.9 million of adjustment-related cash payments. [#SEC-8K-2026-07-28]
Prob 65% • Move -4% • Priced-in 35%

Long-term Catalysts

Months to a year

Commercialization and recurring-value expansion
2026-12-31
Continued commercialization of product innovations, double-digit TRCV growth, and stronger Governance Institute bookings could support durable recurring-contract expansion into the second half of 2026. Visibility remains limited because the packet does not provide detailed forward guidance. [#SEC-8K-2026-07-28]
Prob 55% • Move 12% • Priced-in 40%

Risks

Adjustment-related cash payments and GAAP losses could weigh on investor confidence.
Forward-looking statements remain subject to significant risks and uncertainties. [#SEC-8K-2026-07-28]
Low coverage and unavailable analyst consensus or post-earnings revisions.
Revenue growth may not sustain if healthcare customer spending or bookings weaken.
Weak cash conversion despite adjusted profitability.

Peers

Symbol	Summary
KIDS	Closest by market capitalization and sector classification, but operates in pediatric orthopedic devices; only a loose operating comparison.
NPCE	Similar small-cap healthcare-device classification, but focused on neuromodulation technology; limited comparability.
OFIX	Small-cap orthopedic-device peer with healthcare exposure; useful for size context but not a clean business-model match.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-07-29

AI Stock Memo: NRC - NRC Health - RankAlpha